Three leading executives in the booming field of gene therapy debated the question of whether the pricey therapies should be reimbursed based on whether or not they cure patients.
from Forbes Real Time https://www.forbes.com/sites/arleneweintraub/2017/12/01/gene-therapy-is-booming-but-how-will-we-manage-the-costs/
via IFTTT
No comments:
Post a Comment